Marathon Trading Investment Management LLC Invests $1.22 Million in DexCom, Inc. (NASDAQ:DXCM)

Marathon Trading Investment Management LLC purchased a new stake in DexCom, Inc. (NASDAQ:DXCM) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 15,654 shares of the medical device company’s stock, valued at approximately $1,217,000.

A number of other hedge funds have also added to or reduced their stakes in the stock. Forvis Mazars Wealth Advisors LLC lifted its holdings in shares of DexCom by 0.7% in the fourth quarter. Forvis Mazars Wealth Advisors LLC now owns 17,481 shares of the medical device company’s stock valued at $1,359,000 after purchasing an additional 118 shares in the last quarter. Principal Securities Inc. raised its position in DexCom by 3.4% in the 4th quarter. Principal Securities Inc. now owns 4,069 shares of the medical device company’s stock valued at $316,000 after buying an additional 135 shares during the last quarter. Larson Financial Group LLC lifted its stake in DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock valued at $37,000 after acquiring an additional 137 shares in the last quarter. Crossmark Global Holdings Inc. lifted its stake in DexCom by 1.0% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 18,778 shares of the medical device company’s stock valued at $1,259,000 after acquiring an additional 182 shares in the last quarter. Finally, GPS Wealth Strategies Group LLC boosted its holdings in DexCom by 13.2% during the 4th quarter. GPS Wealth Strategies Group LLC now owns 1,587 shares of the medical device company’s stock worth $123,000 after acquiring an additional 185 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Trading Down 9.1 %

NASDAQ:DXCM opened at $70.72 on Tuesday. The company has a market cap of $27.64 billion, a P/E ratio of 49.45, a P/E/G ratio of 2.30 and a beta of 1.28. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The stock’s fifty day moving average price is $84.68 and its two-hundred day moving average price is $77.00.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. As a group, analysts expect that DexCom, Inc. will post 2.03 EPS for the current year.

Insider Activity at DexCom

In other news, CEO Kevin R. Sayer sold 33,359 shares of DexCom stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the completion of the sale, the chief executive officer now owns 319,037 shares in the company, valued at approximately $27,727,505.67. This trade represents a 9.47 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Jacob Steven Leach sold 2,634 shares of the firm’s stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $228,920.94. Following the completion of the sale, the chief operating officer now directly owns 268,644 shares in the company, valued at $23,347,850.04. This represents a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 38,083 shares of company stock valued at $3,309,794. Corporate insiders own 0.30% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on DXCM. Baird R W upgraded shares of DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Redburn Atlantic upgraded shares of DexCom from a “neutral” rating to a “buy” rating and increased their price objective for the company from $85.00 to $115.00 in a research note on Monday, February 3rd. Citigroup boosted their target price on DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a research note on Tuesday, March 4th. Morgan Stanley increased their price target on DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a research report on Friday, February 14th. Finally, Wells Fargo & Company reiterated an “overweight” rating on shares of DexCom in a report on Saturday. Four research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, DexCom has a consensus rating of “Moderate Buy” and a consensus target price of $99.82.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.